RTP Mobile Logo
Questions from the Community: Clinical Investigators Provide Their Perspectives on Challenging Issues and Ongoing Research in the Management of Multiple Myeloma
Released April 2016

Proceedings from Part 2 of a 2-part satellite symposia series during the 57th ASH Annual Meeting. Featuring perspectives from Drs Rafael Fonseca, Irene M Ghobrial, Ola Landgren, Xavier Leleu and Philip L McCarthy. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY

    Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2015, and 56,630 individuals died from these diseases. Of importance, currently more than 60 drug products are labeled for use in the management of hematologic cancers, comprising more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses quite a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a CME symposium during the 57th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology to frame a relevant discussion of the optimal management of multiple myeloma (MM). By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.


    LEARNING OBJECTIVES
    • Appraise recent data on therapeutic advances and changing practice standards in MM, amyloidosis and Waldenström macroglobulinemia (WM), and integrate this information, as appropriate, into current clinical care.
    • Develop a risk-adapted treatment plan for patients with smoldering MM, considering the roles of observation and active treatment.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Customize the use of induction and maintenance therapeutic approaches in the post-transplant and nontransplant settings based on patient- and disease-related factors, including cytogenetic profile.
    • Consider available research data and other clinical factors in the best-practice selection, sequencing or combining of carfilzomib and pomalidomide in the nonresearch care of patients with relapsed, refractory MM.
    • Recognize the recent FDA approvals of panobinostat, daratumumab and ixazomib, and effectively identify patients for whom treatment with these novel agents may be appropriate.
    • Develop an evidence-based algorithm for the use of stem cell transplant, chemotherapy and/or novel targeted agents for the management of primary amyloidosis.
    • Appreciate the recent FDA approval of ibrutinib for patients with WM, and safely integrate this agent, where applicable, into clinical practice.
    • Recall new data with investigational agents demonstrating promising activity in MM, WM and amyloidosis.
    • Assess the ongoing clinical trials evaluating innovative developmental approaches for MM, WM and amyloidosis, and obtain consent from appropriate patients for study participation.
    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Rafael Fonseca, MD
    Getz Family Professor of Cancer
    Chair, Department of Internal Medicine
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Advisory Committee: Applied Bioscience, Bristol-Myers Squibb Company; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Sanofi; Contracted Research: Amgen Inc, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi.

    Irene M Ghobrial, MD
    Associate Professor in Medicine
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Ola Landgren, MD, PhD
    Chief, Myeloma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology.

    Xavier Leleu, MD, PhD
    Professor of Hematology
    Service d’Hématologie et Thérapie Cellulaire
    Pôle Régional de Cancérologie
    Hôpital de La Milétrie, CHU
    Poitiers, France

    Consulting Agreements: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Go-Pharma, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Takeda Oncology, Teva Oncology.

    Philip L McCarthy, MD
    Professor of Oncology and Internal Medicine
    BMT Program
    Roswell Park Cancer Institute and State University of New York at Buffalo
    Buffalo, New York

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Karyopharm Therapeutics, Sanofi.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Margaret A Deutsch, MD
    Clinical Associate
    Duke Raleigh Hematology-Oncology
    Raleigh, North Carolina

    No relevant conflicts of interest to disclose.

    Lyle Feinstein, MD
    Miami Cancer Institute
    Miami, Florida

    No relevant conflicts of interest to disclose.

    Raymond Lobins, DO
    Hematology/Oncology
    Lake County University Hospitals
    Mentor, Ohio

    No relevant conflicts of interest to disclose.

    Jason Melear, MD
    Texas Oncology
    Austin, Texas

    No relevant conflicts of interest to disclose.

    Neil I Morganstein, MD
    Chair of Leukemia/Lymphoma Board
    Carol G Simon Cancer Center
    Overlook Medical Center
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Takeda Oncology and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

    Last review date: April 2016
    Expiration date: April 2017

Acknowledge and close

View video: